3 Reasons to Sell CHE and 1 Stock to Buy Instead
This article recommends selling Chemed (CHE) stock due to disappointing long-term revenue growth, a shrinking adjusted operating margin, and declining return on invested capital (ROIC). The author suggests that despite a fair valuation, the stock's upside is limited compared to potential downside risks. Instead, it advises investors to look for high-quality, under-the-radar stocks with strong momentum, mentioning past performers like Nvidia and Tecnoglass.
Chemed Stock Down 15% in a Year as One Fund Builds a $5.56 Million Stake
Barington Companies Management has disclosed a new $5.56 million stake in Chemed (NYSE:CHE) by acquiring 13,000 shares, despite the stock being down over 15% in the past year. Chemed operates in hospice care (VITAS) and plumbing services (Roto-Rooter), and the investment suggests conviction in its stable cash generation and balance sheet strength, even after a quarter with a slight dip in adjusted EPS. The company maintains its full-year guidance and has no current or long-term debt.
Chemed Corporation Board of Directors Authorizes an Additional $300 Million for Stock Repurchase and Declares Quarterly Dividend of 60 Cents
Chemed Corporation (NYSE:CHE) announced that its Board of Directors has authorized an additional $300 million for its existing stock repurchase program, to be funded by cash from operations and its revolving credit facility. The company also declared a quarterly cash dividend of 60 cents per share, payable on March 13, 2026, marking its 219th consecutive quarterly dividend. Chemed operates two wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter.
Chemed Corporation Authorizes $300 Million Stock Repurchase and Declares Quarterly Dividend
Chemed Corporation has authorized an additional $300 million for its stock repurchase program, to be funded by operational cash and a revolving credit facility. The company's Board of Directors also declared a quarterly cash dividend of 60 cents per share, consistent with the previous quarter, marking its 219th consecutive quarterly dividend. Chemed operates VITAS Healthcare and Roto-Rooter, and this announcement reflects its commitment to shareholder returns, though some analysts suggest it may indicate a lack of growth investment opportunities.
Chemed backs $300M share buyback and a 219th straight dividend
Chemed Corporation has authorized an additional $300 million for its existing share repurchase program, to be funded by cash from operations and a revolving credit facility. The company also declared a quarterly cash dividend of $0.60 per share, payable on March 13, 2026, marking its 219th consecutive quarterly dividend over 54 years. Chemed operates through its subsidiaries VITAS Healthcare and Roto-Rooter.
Chemed Corporation Board of Directors Authorizes an Additional $300 Million for Stock Repurchase and Declares Quarterly Dividend of 60 Cents
Chemed Corporation announced that its Board of Directors authorized an additional $300 million for its existing share repurchase program, to be funded by cash from operations and its revolving credit facility. The company also declared a quarterly cash dividend of 60 cents per share, payable on March 13, 2026, marking its 219th consecutive quarterly dividend. Chemed operates two subsidiaries: VITAS Healthcare, a hospice care provider, and Roto-Rooter, a plumbing and drain cleaning service.
Chemed approves $300 million stock buyback, declares quarterly dividend
Chemed Corporation has announced an additional $300 million for its stock repurchase program, emphasizing its commitment to shareholder returns. The company also declared a quarterly cash dividend of 60 cents per share, marking its 219th consecutive quarterly dividend. This news comes shortly after Jefferies downgraded Chemed's stock to Hold, citing concerns with its Roto-Rooter business segment.
Chemed Corporation Board of Directors Authorizes an
Chemed Corporation's Board of Directors has approved an additional $300 million for its stock repurchase program, to be funded by operations and its revolving credit facility. The company also declared a quarterly cash dividend of 60 cents per share, payable on March 13, 2026, marking its 219th consecutive quarterly dividend. Chemed operates two main subsidiaries: VITAS Healthcare and Roto-Rooter.
Thrivent Financial for Lutherans Trims Stake in Chemed Corporation $CHE
Thrivent Financial for Lutherans significantly reduced its stake in Chemed Corporation ($CHE) by 96.3% in the third quarter, selling 86,865 shares and retaining 3,348 shares valued at $1.499 million. This divestment comes as CEO Kevin J. McNamara also sold 2,000 shares in November, reducing his position by over 2%. Despite these sales, Chemed maintains a "Moderate Buy" consensus rating from analysts with a price target of $555.50.
Chemed Corporation $CHE Shares Acquired by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. significantly increased its stake in Chemed Corporation ($CHE) by 6.5% during the third quarter, bringing its total holdings to 80,080 shares valued at approximately $35.86 million. This move makes Envestnet one of several institutional investors accumulating shares, with hedge funds and institutions now owning 95.85% of Chemed. Analysts maintain a "Moderate Buy" rating for Chemed, alongside recent insider selling by CEO Kevin J. Mcnamara.
Allianz Asset Management GmbH Has $3.25 Million Holdings in Chemed Corporation $CHE
Allianz Asset Management GmbH significantly reduced its stake in Chemed Corporation (NYSE:CHE) by 53.3% in the third quarter, bringing its total holdings to $3.25 million. This divestment comes amidst various other institutional investors adjusting their positions in Chemed, and follows an insider stock sale by CEO Kevin J. Mcnamara. Analyst ratings for Chemed are mixed, with a consensus "Moderate Buy" despite recent downgrades and price objective reductions.
Chemed Corp: Defensive Outperformer Tests Its Nerves As The Rally Starts To Stall
Chemed Corp, a defensive healthcare company combining hospice care and plumbing services, has outperformed the broader market over the past year. However, recent choppy trading and a cooling 90-day trend have raised questions among investors about whether its rally will continue or if a period of consolidation is ahead. Despite recent stock dips, analysts maintain a constructive view, with consensus ratings leaning towards "Buy" or "Outperform" due to the company's resilient business model and consistent earnings.
Candriam S.C.A. Has $19.28 Million Stock Position in Chemed Corporation $CHE
Candriam S.C.A. decreased its stake in Chemed Corporation by 22.6% in the third quarter of 2025, now holding 43,056 shares valued at approximately $19.28 million. The stock currently has a "Moderate Buy" rating with an average target price of $555.50 from analysts. Chemed's CEO, Kevin J. McNamara, also sold 2,000 shares in November, reducing his holding by 2.08%.
Alps Advisors Inc. Buys 10,845 Shares of Chemed Corporation $CHE
Alps Advisors Inc. increased its stake in Chemed Corporation by 32.4% in the third quarter, purchasing an additional 10,845 shares to own a total of 44,295 shares valued at approximately $19.83 million. Other institutional investors like Acadian Asset Management LLC, AQR Capital Management LLC, and Norges Bank also made significant moves, with institutions collectively owning 95.85% of Chemed's stock. CEO Kevin J. McNamara sold 2,000 shares, reducing his holding, while analysts maintain a "Moderate Buy" rating for CHE with a consensus price target of $555.50.
Ranger Investment Management L.P. Has $17.91 Million Holdings in Chemed Corporation $CHE
Ranger Investment Management L.P. significantly reduced its stake in Chemed Corporation (CHE) by 32.8% in Q3, now holding 40,005 shares valued at $17.91 million. Conversely, other major institutions like Acadian Asset Management, AQR Capital Management, and Norges Bank increased or initiated substantial positions, pushing institutional ownership to 95.85%. Analysts maintain a "Moderate Buy" consensus for Chemed, with a target price of $555.50 against its current trading price of around $450.82.
Chemed Corporation $CHE Shares Purchased by Van Berkom & Associates Inc.
Van Berkom & Associates Inc. significantly increased its stake in Chemed Corporation (NYSE:CHE) by 33.0% in the third quarter, now owning 1.17% of the company's stock valued at $76.48 million. Other institutional investors also bought shares, while Chemed's CEO sold 2,000 shares. The company recently declared a quarterly dividend of $0.60 per share, and analysts currently have a "Moderate Buy" rating with an average price target of $555.50.
Chemed Corporation (CHE): A Bull Case Theory
This article summarizes a bull thesis on Chemed Corporation (CHE) from Valueinvestorsclub.com. Despite recent stock depreciation and temporary headwinds for its VITAS hospice segment, the company's strong free cash flow, high ROIC, and fundamentally attractive hospice market position suggest a good risk/reward profile. The author believes the current valuation is overly pessimistic, pricing in permanent impairment in VITAS and undervaluing future growth.
Price-Driven Insight from (CHE) for Rule-Based Strategy
This article provides a price-driven insight for Chemed Corp (NYSE: CHE) for rule-based strategies. It highlights weak sentiment in the near-term that may lead to a resumption of long-term weakness and identifies an exceptional short setup with a high risk-reward ratio. The analysis details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and support/resistance levels.
Y Intercept Hong Kong Ltd Lowers Stock Position in Chemed Corporation $CHE
Y Intercept Hong Kong Ltd reduced its stake in Chemed Corporation ($CHE) by 24.1% in the third quarter, selling 2,374 shares and holding 7,463 shares valued at $3.34 million. Chemed has a "Moderate Buy" consensus rating from analysts with a target price of $555.50, despite recent downgrades. Insider activity shows CEO Kevin J. McNamara sold 2,000 shares in November.
Chemed Corp (CHE) Stock Analysis: Exploring a 24.34% Potential Upside in the Healthcare Sector
Chemed Corporation (CHE) is analyzed as a compelling investment opportunity in the healthcare sector, offering hospice care through VITAS and plumbing services via Roto-Rooter. The company demonstrates strong financial performance with positive revenue growth and EPS, a conservative dividend policy, and potential for a 24.34% upside based on analyst ratings. Despite mixed technical indicators, its diversified operations and solid financials suggest continued growth and shareholder value enhancement for long-term investors.
3 Low-Volatility Stocks We Find Risky
This article identifies three low-volatility stocks—Chemed (CHE), The Pennant Group (PNTG), and Aramark (ARMK)—that the author considers risky despite their apparent stability. The author provides specific concerns for each company, such as declining margins, slow growth, and poor free cash flow, and instead recommends a curated list of "Market-Beating Stocks" for better growth opportunities.
Why Chemed (CHE) Shares Are Sliding Today
Shares of Chemed Corporation fell by 4.2% after Jefferies downgraded the stock to 'Hold' from 'Buy' and reduced its price target to $475 from $550. The downgrade was prompted by concerns regarding the profitability of Chemed's Roto-Rooter business segment, with analysts indicating that a return to normal growth for this unit in 2026 is unlikely. This follows a previous drop related to a negative update on its VITAS hospice business guidance and unexpected weakness in Roto-Rooter's residential demand.
Schwartz Investment Counsel Inc. Has $49.71 Million Stock Position in Chemed Corporation $CHE
Schwartz Investment Counsel Inc. significantly reduced its stake in Chemed Corporation ($CHE) by 20.6% in the third quarter, now holding 111,033 shares valued at $49.71 million. Despite a slight miss on Q3 earnings and revenue estimates, Chemed provided optimistic FY2025 guidance exceeding analyst expectations and pays a quarterly dividend. Insider trading activity included CEO Kevin J. McNamara selling 2,000 shares, reducing his ownership to 94,197 shares.
Chemed Corp: Defensive Compounder Grinds Higher as Wall Street Stays Quietly Bullish
Chemed Corp's stock has shown quiet resilience, steadily grinding higher despite market volatility, driven by its defensive business model of hospice care (VITAS) and plumbing services (Roto Rooter). Analysts remain generally bullish, seeing further upside even as the stock approaches its 52-week high, thanks to predictable cash generation and strong management. The company's consistent performance positions it as a quality defensive compounder for long-term investors.
Chemed Corporation $CHE Stock Holdings Lowered by Harel Insurance Investments & Financial Services Ltd.
Harel Insurance Investments & Financial Services Ltd. significantly reduced its stake in Chemed Corporation (CHE) by 24.4% in the third quarter of 2025. Despite this reduction, other large institutions like Acadian Asset Management, AQR Capital Management, and Norges Bank either increased their holdings or initiated new positions, indicating continued institutional interest. Chemed, which holds a consensus "Moderate Buy" rating from analysts, recently missed its quarterly EPS but issued positive FY2025 guidance.
Evergreen Capital Management LLC Has $9.07 Million Stock Position in Chemed Corporation $CHE
Evergreen Capital Management LLC significantly increased its stake in Chemed Corporation (NYSE:CHE) by 95.8% in the third quarter, now holding 20,262 shares valued at approximately $9.07 million. Despite Chemed missing Q3 earnings and revenue expectations, the company provided optimistic FY2025 EPS guidance averaging $22.00–$22.30. Institutional investors collectively own a substantial 95.85% of Chemed's stock, even after a recent insider sale by the CEO.
EULAV Asset Management Lowers Holdings in Chemed Corporation $CHE
EULAV Asset Management significantly reduced its stake in Chemed Corporation (NYSE:CHE) by 22.9% in Q3, selling over 28,000 shares but still retaining a substantial holding. While EULAV decreased its position, other institutional investors like Acadian, AQR, and Norges Bank increased their exposure, contributing to a high institutional ownership of 95.85%. Chemed recently missed Q3 EPS estimates, provided FY2025 guidance of 22.00–22.30 EPS, and currently holds a "Moderate Buy" consensus rating with an average analyst price target of $574.25.
Chemed Corporation (NYSE:CHE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Chemed Corporation (NYSE:CHE) has received a "Moderate Buy" consensus recommendation from six brokerages, with an average 1-year target price of $574.25. Despite narrowly missing Q3 earnings expectations, the company's FY2025 EPS guidance is above street estimates, and institutional ownership remains high. CEO Kevin J. Mcnamara recently sold shares, but many institutions significantly increased their holdings.
(CHE) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth analysis of Chemed Corp (NYSE: CHE) for institutional tactics, highlighting near-term sentiment shifts, resistance testing, and an exceptional short setup. It details AI-generated trading strategies including position trading, momentum breakout, and risk hedging, alongside a multi-timeframe signal analysis. The piece emphasizes the use of predictive AI for optimizing trading decisions.
Did you know Roto-Rooter is based in Cincinnati? What to know
Roto-Rooter, a well-known service company, has been based in downtown Cincinnati for nine decades. The company has seen significant growth in recent years, more than doubling its sales in the last decade to nearly a billion dollars annually. This growth has been achieved through re-acquiring franchises across the country, expanding on its core drain-unclogging service patented in 1935.
Chemed Corp (CHE) Investor Outlook: Analysts Eye 35.50% Upside Potential
Chemed Corp (CHE), a healthcare and plumbing services provider, currently has a market capitalization of $6.18 billion and analysts see a significant upside potential of 35.50%. Despite a minor stock decline, the company shows strong financial health with a robust ROE of 24.11% and solid free cash flow. Analysts have issued 4 buy ratings, projecting an average target price of $574.25, making it an attractive prospect for investors seeking growth and stability.
Parent of VITAS and Roto-Rooter sets date to share Q4 results
Chemed Corporation (NYSE: CHE) announced it will release its fourth-quarter 2025 financial results on Wednesday, February 25, 2026, after market close. A conference call and webcast will follow on Thursday, February 26, 2026, at 10:00 a.m. ET to discuss the results and provide a business update. The company operates two key subsidiaries: VITAS Healthcare, a major hospice care provider, and Roto-Rooter, a leading plumbing and drain cleaning service.
Chemed Corp: Quiet Compounder Or Exhausted Winner? What The Latest Numbers Say
Chemed Corp's stock has shown resilient growth over the past year, with a steady 8% gain for investors, excluding dividends. The company operates a unique two-engine business model consisting of VITAS (hospice care) and Roto-Rooter (plumbing and drain-cleaning), providing stability across economic cycles. Analysts generally hold a "soft Buy" rating, anticipating continued earnings growth but noting that future returns will hinge on fundamental performance rather than multiple expansion.
Chemed Corp: Quiet Compounder Or Exhausted Winner? What The Latest Numbers Say
Chemed Corp's stock has shown resilient performance over the past year, with an 8% gain, distinguishing it in a volatile market due to its stable earnings and niche services. Analysts are cautiously bullish, noting the company's strong defensive business model combining hospice care (VITAS) and plumbing services (Roto-Rooter), yet suggesting future returns will depend on continued earnings growth rather than multiple expansion. The article explores whether this low-volatility winner, trading near its 52-week high, still has significant room for growth or if its current price reflects perfection after a strong run.
The Truth About Chemed Corp: Quiet Stock, Loud Money Moves – Are You Sleeping On CHE?
Chemed Corp (CHE) operates in the stable sectors of hospice care (VITAS) and plumbing services (Roto-Rooter), offering defensive investment potential compared to volatile meme stocks. Despite not being a social media trend, CHE demonstrates consistent revenue, solid profitability, and a track record of shareholder returns, making it an attractive option for long-term investors seeking lower drama and compound returns. The article suggests that while it isn't a quick flip, its premium price and essential service model make it a strong candidate for a core portfolio position after thorough research.
VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Stock Holdings in Chemed Corporation $CHE
VIRGINIA RETIREMENT SYSTEMS ET Al significantly reduced its stake in Chemed Corporation by 43.4% in Q3, selling 2,400 shares and retaining 3,136 shares valued at $1.404 million. Despite missing Q3 EPS estimates, Chemed provided FY2025 guidance above analyst expectations, indicating a potential rebound. The company shows high institutional ownership (95.85%) and has recently paid a quarterly dividend of $0.60 per share.
Chemed Corporation to Release Fourth Quarter 2025 Financial Results on February 25, 2026
Chemed Corporation announced it will release its Q4 2025 financial results on February 25, 2026, after market close, with a conference call and webcast scheduled for February 26, 2026, at 10 a.m. ET. The company, which operates VITAS Healthcare and Roto-Rooter, will discuss its performance and business update during the call. Insider trading activity and hedge fund movements for CHE stock are also highlighted.
Chemed to Report Fourth-Quarter 2025 Earnings February 25, Related Conference Call to Be Held ...
Chemed Corporation announced it will release its fourth-quarter 2025 financial results on Wednesday, February 25, 2026, after the close of trading. A conference call and webcast will follow on Thursday, February 26, 2026, at 10 a.m. ET to discuss the results and provide a business update. Chemed operates VITAS Healthcare, a hospice care provider, and Roto-Rooter, a plumbing and drain cleaning service.
Chemed to Report Fourth-Quarter 2025 Earnings February 25, Related Conference Call to Be Held on February 26
Chemed Corporation has announced it will release its fourth-quarter 2025 financial results on February 25, 2026, after market close. The company will host a conference call and webcast on February 26, 2026, at 10 a.m. ET to discuss the results and provide a business update. Information on accessing the webcast and teleconference registration is provided for interested participants.
Chemed to Report Fourth-Quarter 2025 Earnings February 25, Related Conference Call to Be Held on February 26
Chemed Corporation announced it will release its fourth-quarter 2025 financial results on Wednesday, February 25, 2026, after the market closes. The company will then host a conference call and webcast on Thursday, February 26, 2026, at 10 a.m. ET to discuss these results and provide business updates.
Chemed Corporation $CHE Holdings Reduced by Smith Salley Wealth Management
Smith Salley Wealth Management reduced its stake in Chemed Corporation (NYSE:CHE) by 17.0%, selling 2,981 shares and ending the quarter with 14,570 shares valued at $6.52 million. Despite this reduction, several other large institutions like Acadian Asset Management, AQR Capital Management, and Norges Bank significantly increased their holdings, bringing institutional ownership to approximately 95.85%. Chemed missed its quarterly EPS and revenue estimates but provided optimistic FY2025 guidance, with analysts setting an average target price of $574.25, indicating potential upside from its current price of around $431.
Chemed Corporation to Release Fourth Quarter 2025 Financial Results on February 25, 2026
Chemed Corporation announced it will release its Q4 2025 financial results on February 25, 2026, after market close, followed by a conference call and webcast on February 26, 2026, at 10 a.m. ET. The company operates VITAS Healthcare, the largest U.S. hospice care provider, and Roto-Rooter, a leading plumbing service. The announcement includes an AI-generated summary, insider trading activity, revenue data, hedge fund activity, and analyst ratings/price targets for CHE.
Chemed Corporation's (NYSE:CHE) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Chemed Corporation (NYSE:CHE) has experienced a 3.5% stock price decline over the past three months, but its financial fundamentals appear sound. The company's Return on Equity (ROE) stands at an impressive 26%, significantly higher than the industry average. Despite strong profitability and a low payout ratio suggesting considerable reinvestment, Chemed's earnings growth has been flat over the last five years, raising questions about factors limiting its expansion.
Technical Reactions to CHE Trends in Macro Strategies
This article from Stock Traders Daily analyzes Chemed Corp (NYSE: CHE), noting stable neutral readings in shorter horizons that could signal an easing of a long-term weak bias. It highlights an exceptional 36.6:1 risk-reward setup targeting a 10.6% gain versus a 0.3% risk. The report also provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Riverbridge Partners LLC Cuts Stake in Chemed Corporation $CHE
Riverbridge Partners LLC reduced its stake in Chemed Corporation (NYSE:CHE) by 8.1% in Q3 2025, selling 5,029 shares and now holding 56,975 shares valued at approximately $25.51 million. Despite Riverbridge's reduction, other institutional investors like Norges Bank and AQR Capital Management significantly increased their holdings, bringing overall institutional ownership to about 95.85%. Chemed recently missed its quarterly EPS and slightly missed revenue expectations but provided FY2025 guidance above analyst averages and declared a $0.60 quarterly dividend.
Should Investors Hold Chemed Stock in Their Portfolio Now?
Chemed Corporation (CHE) shows growth potential, particularly in its VITAS hospice care segment due to increased admissions and strategic initiatives. The Roto-Rooter segment also demonstrates resilience, achieving modest revenue growth despite market challenges. However, the company faces risks from macroeconomic headwinds, such as inflation and tariffs, which could impact profitability, and competition in both its operating segments.
(CHE) and the Role of Price-Sensitive Allocations
This article provides an in-depth analysis of Chemed Corp (NYSE: CHE) based on AI-generated signals, highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels. The analysis identifies an exceptional 38.1:1 risk-reward setup targeting an 11.1% gain versus 0.3% risk.
Chemed Corporation (NYSE:CHE) Given Average Rating of "Moderate Buy" by Analysts
Chemed Corporation (NYSE:CHE) has received a consensus "Moderate Buy" rating from six analysts, with an average 12-month price target of $574.25. Despite narrowly missing quarterly earnings and revenue estimates, the company issued optimistic FY2025 EPS guidance. Insider selling by the CEO and significant institutional ownership were also noted.
Ranger Investment Management L.P. Has $28.98 Million Stock Position in Chemed Corporation $CHE
Ranger Investment Management L.P. significantly increased its stake in Chemed Corporation (NYSE:CHE) by 13.3% in Q2, now owning 59,505 shares valued at $28.98 million, making it their 19th largest holding. Despite a recent insider sale by CEO Kevin J. McNamara, institutional investors hold a substantial 95.85% of the stock. Analysts currently rate Chemed as a "Moderate Buy" with a consensus price target of $574.25, even after the company slightly missed quarterly EPS estimates but provided positive FY2025 guidance.
Bank of Nova Scotia Purchases 4,799 Shares of Chemed Corporation $CHE
Bank of Nova Scotia increased its holding in Chemed Corporation (NYSE:CHE) by 114.3% in the second quarter, acquiring an additional 4,799 shares to total 8,999 shares valued at $4.38 million. Chemed reported quarterly EPS of $5.27, missing estimates, and set its FY2025 EPS guidance between $22.00 and $22.30. Several analysts maintain a "Buy" or "Hold" rating on Chemed, with a consensus target price of $574.25.
